Cytogen’s new investors
Lilly purchases 135,881 shares of common stock in the monoclonal antibody R&D company at a 25% premium to the market under an April agreement that grants Lilly a non-exclusive worldwide license to development and market certain cancer products using Cytogen technology. In addition, Italian drug firm Bracco Chimica purchases 250,000 Cytogen shares at $8 per share as part of a September R&D agreement covering magnetic resonance imaging enhancement agents.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.